Find a Doctor

DA
Areas of Expertise

Daniel Aletaha

European League Against Rheumatism Standing Committees
Male

Bio

They have been an author on 242 peer reviewed articles and participated in 1 clinical trial in the past 15 years.

Areas of Expertise

Contact

CH

Latest Advances

Latest Advance
Study
  • Condition: Rheumatic Diseases
  • Journal: Clinical rheumatology
  • Treatment Used: Leflunomide
  • Number of Patients: 222
  • Published —
Leflunomide, an inhibitor of pyrimidine synthesis, is used for the treatment of rheumatic diseases, which are prevalent in women of childbearing age. The purpose of this review study was to evaluate the safety of leflunomide in pregnant women.
Latest Advance
Study
  • Condition: Rheumatoid Arthritis (RA)
  • Journal: Annals of the rheumatic diseases
  • Treatment Used: Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Number of Patients: 274
  • Published —
This study determined if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
Latest Advance
Study
  • Condition: Rheumatoid Arthritis (RA)
  • Journal: Rheumatic diseases clinics of North America
  • Treatment Used: Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug (csDMARD)Therapy vs. Methotrexate (MTX) as the Initial Treatment of Choice
  • Number of Patients: 0
  • Published —
This article discusses whether triple conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) improve upon methotrexate (MTX) as the initial treatment of choice for patients with rheumatoid arthritis (RA).
Latest Advance
Study
  • Condition: Early Inflammatory Arthritis
  • Journal: Arthritis research & therapy
  • Treatment Used: Infliximab plus Methotrexate
  • Number of Patients: 99
  • Published —
This study explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)? antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very early inflammatory arthritis.
Latest Advance
Study
  • Condition: Active Rheumatoid Arthritis
  • Journal: Lancet (London, England)
  • Treatment Used: Sirukumab
  • Number of Patients: 878
  • Published —
This study tested the safety and efficacy of treating active rheumatoid arthritis in patients who reacted negatively to anti-TNF therapy with sirukumab.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 32
  • Start Date: November 24, 2017
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

All Publications
View All

Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials

Contact

CH

Insurance

Contact them to find out if they accept your insurance plan.